Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

Ignatiadis, M; Litière, S; Rothe, F; Riethdorf, S; Proudhon, C; Fehm, T; Aalders, K; Forstbauer, H; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, K; Janni, W; Piccart, M; Sotiriou, C; Rack, B; Pierga, J-Y

Ignatiadis, M; Litière, S; Rothe, F; Riethdorf, S; Proudhon, C; Fehm, T; Aalders, K; Forstbauer, H; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, K; Janni, W; Piccart, M; Sotiriou, C; Rack, B; Pierga, J-Y.

Affiliation

Ignatiadis M; Department of Medical Oncology, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium. Electronic address: michail.ignatiadis@bordet.be.
Litière S; European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
Rothe F; Breast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium.
Riethdorf S; Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Proudhon C; Circulating Tumor Biomarker Laboratory, Institut Curie, Paris, France.
Fehm T; Department of Gynecology and Obstetrics, Universitätsklinikum, Düsseldorf, Germany.
Aalders K; European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
Forstbauer H; Society for Oncological Studies, Praxismanagement und -Logistik (GOSPL), Troisdorf, Germany.
Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Brain E; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
Vuylsteke P; Université catholique de Louvain, CHU Ucl Namur, Belgium.
Guardiola E; Hospital Center of Dracénie, Draguignan, France.
Lorenz R; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany.
Pantel K; Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tryfonidis K; European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
Janni W; Department of Gynecology and Obstetrics, Universitaetsklinikum Ulm, Ulm, Germany.
Piccart M; Department of Medical Oncology, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium.
Sotiriou C; Department of Medical Oncology, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Universite ´ Libre de Bruxelles, Brussels, Belgium.
Rack B; Department of Gynecology and Obstetrics, Universitaetsklinikum Ulm, Ulm, Germany.
Pierga JY; Circulating Tumor Biomarker Laboratory, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie, Université Paris Descartes, Paris, France.

Ann Oncol ; 29(8): 1777-1783, 2018 08 01.

Article de En | MEDLINE | ID: mdl-29893791

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Trastuzumab / Antinéoplasiques immunologiques / Cellules tumorales circulantes Type d'étude: Clinical_trials / Etiology_studies Limites: Adult / Aged / Female / Humans / Middle aged Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2018 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google